Browse Category

SWX:ROG 22 June 2025 - 7 February 2026

Eli Lilly stock price falls over 2% as Medicare puts Trulicity on 2028 price-talk list

Eli Lilly stock price falls over 2% as Medicare puts Trulicity on 2028 price-talk list

Eli Lilly shares closed down 2.3% at $1,039.51 Tuesday, then rose 0.3% after hours. U.S. Medicare officials named Lilly’s Trulicity among 15 drugs for 2028 price negotiations. The stock has dropped three straight sessions and now trades about 8% below its Jan. 8 peak. Investors await Lilly’s Feb. 4 earnings for updates on diabetes and obesity drug trends.
Roche stock hovers near a 52-week high as investors brace for Thursday’s results

Roche stock hovers near a 52-week high as investors brace for Thursday’s results

Roche participation shares closed Friday at 348.10 Swiss francs, up 0.06% and near a 52-week high. The company will report full-year 2025 results before the Swiss market opens on Jan. 29, followed by a management webcast. Investors are watching for 2026 guidance and updates on drug launches and diagnostics demand. The Swiss Market Index fell 0.61% Friday.
ImmunityBio stock tumbles after glioblastoma update; what to watch before Monday

ImmunityBio stock tumbles after glioblastoma update; what to watch before Monday

ImmunityBio shares fell 12.1% to $6.45 Friday after the company previewed new data from its Phase 2 glioblastoma trial, with full results due Jan. 31. The stock traded heavily between $7.88 and $6.43. Median overall survival in the study was “not yet reached” as of Jan. 22, with 19 of 23 patients alive. Investors are watching for more details on durability, safety, and trial design.
Structure Therapeutics stock jumps 14% as Roche-Genentech patent deal back in focus

Structure Therapeutics stock jumps 14% as Roche-Genentech patent deal back in focus

Structure Therapeutics shares surged about 14% midday Tuesday after a recent SEC filing revealed a $100 million upfront patent license deal with Roche’s Genentech for an oral GLP-1 drug. The stock rose to $79.24, up $9.88 from Monday’s close, as investors re-evaluated obesity-drug makers during the J.P. Morgan Healthcare Conference.
Roche stock: $570 million MediLink cancer-drug deal puts Swiss shares back in focus

Roche stock: $570 million MediLink cancer-drug deal puts Swiss shares back in focus

Roche agreed to pay MediLink $570 million upfront and in near-term milestones for ex-China rights to experimental cancer drug YL201. Roche shares closed up 0.4% at 340.80 Swiss francs after the deal was announced. The Swiss SMI index hit a record high. Investors await Roche’s appearance at the JPM Healthcare Conference on Jan. 12 and its full-year earnings on Jan. 29.
Swiss Stock Market Today, November 18, 2025: SMI Slips as Roche Soars, ABB, Zurich and ams-Osram Drag the Index

Swiss Stock Market Today, 21 November 2025: SMI Holds Near Flat as Tech Slides and Defensives Lift Zurich

The Swiss Market Index erased early losses to trade 0.08% higher at 12,553 points by mid-morning Friday, as investors shifted from tech to defensive blue chips. UBS shares fell after a $3 billion buyback, while SGS rose on an acquisition. Nestlé digested a top executive’s retirement, and Schindler’s HR chief exited abruptly. The STOXX 600 dropped 1% amid global tech sell-offs and Fed uncertainty.
Record Highs, $55 B Deals & Data Drama: Wall Street’s Wild Week (Oct 4–5, 2025)

EU Stock Market Today (18 November 2025): STOXX 600 Tumbles 1.8% as AI Bubble Fears Rattle European Shares

European stocks fell sharply Tuesday, with the STOXX 600 dropping 1.8% to a one-month low and posting its steepest daily loss since August. Germany’s DAX and France’s CAC 40 each lost up to 1.9%, while the UK’s FTSE 100 slid 1.3%. A key European volatility gauge jumped to its highest since October. Ocado plunged as much as 20%, while Roche rose nearly 7% on positive drug trial data.
Tariff Shocks & Rate Jitters Ignite Wild 48 Hours in European Markets

Tariff Shocks & Rate Jitters Ignite Wild 48 Hours in European Markets

European stocks hit three-week lows Thursday, then rebounded Friday as the STOXX 600 fell 0.7% before rising 0.3%. U.S. President Trump’s new tariffs on drugs and trucks triggered a 2% drop in major pharma and truck stocks. The Bank of England warned on persistent UK inflation, while the ECB and Swiss National Bank held rates steady. Germany’s consumer confidence improved; Spain’s GDP beat forecasts.
Top 100 Global Biotechnology Companies Revolutionizing Science and Health

Top 100 Global Biotechnology Companies Revolutionizing Science and Health

Pfizer and BioNTech co-developed Comirnaty, the first FDA-approved mRNA COVID-19 vaccine. Roche leads in oncology and diagnostics, while Moderna advanced mRNA vaccines for COVID-19 and other diseases. Illumina dominates DNA sequencing, and CRISPR Therapeutics develops gene-editing therapies for sickle cell disease.
Go toTop